Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 902
- Registration Number
- NCT02425891
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇦Treatment and Prevention Institution Volyn Regional Oncology Dispensary, Lutsk, Ukraine
🇺🇸The Methodist Cancer Center, Houston, Texas, United States
Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer
- Conditions
- Breast Cancer, Metastatic Breast Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 69
- Registration Number
- NCT02424682
Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan
- Conditions
- Postmenopausal Osteoporosis
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 624
- Registration Number
- NCT02422069
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 915
- Registration Number
- NCT02420821
- Locations
- 🇺🇸
Lynn Cancer Institute/Boca Raton Regional Hospital, Boca Raton, Florida, United States
🇺🇸Florida Cancer Specialists - Port Charlotte, Port Charlotte, Florida, United States
🇺🇸Texas Oncology-Baylor Sammons Cancer Center, Dallas, Texas, United States
Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)
- Conditions
- Macular EdemaMacular Degeneration
- Interventions
- Other: Ranibizumab
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2019-06-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT02420132
- Locations
- 🇺🇸
Rocky Mountain Retina, Salt Lake City, Utah, United States
Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 110
- Registration Number
- NCT02419742
- Locations
- 🇮🇳
Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India
🇮🇳Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India
🇮🇳MAX Balaji Hospital, Delhi, India
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT02409355
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States
🇺🇸Marin Cancer Care Inc, Greenbrae, California, United States
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 572
- Registration Number
- NCT02409342
- Locations
- 🇫🇷
Centre D'oncologie de Gentilly, Nancy, France
🇫🇷Centre Hospitalier Regional Sud Reunion, Saint-pierre, France
🇧🇷Centro de Pesquisas Clinicas em Oncologia - CPCO, Cachoeiro de Itapemirim, ES, Brazil
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 139
- Registration Number
- NCT02406092
- Locations
- 🇲🇦
Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique, Rabat, Morocco
🇩🇿Hôpital Dorban CHU Annaba, Service d'Hématologie, Annaba, Algeria
🇩🇿Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie, Tizi Ouzou, Algeria
Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- Device: Accu-Chek Insight Pump System
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 43
- Registration Number
- NCT02403375
- Locations
- 🇦🇹
Medical University Graz, Graz, Austria
🇩🇪Kinderkrankenhaus auf der Bult, Hannover, Germany
🇦🇹Medical University of Vienna-Dept of Pediatrics, Vienna, Austria